iPSC Generation using Peptide Injection and Site-Selective HDAC Inhibition
iPSC Generation using Peptide Injection and Site-Selective HDAC Inhibition
批准号:
7937897
负责人:
Takashi Hamazaki
金额:
$46.54万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-09-30 至 2012-08-31
关键词:
AddressAdultAgricultureAlkylating AgentsAreaBacteriaBindingCellsChemicalsDNADNA AlkylationDNA IntegrationDevelopmentEpithelial CellsFibroblastsFloridaFoodGene ActivationGene DeliveryGene TargetingGene TransferGenerationsGenesGenomeGoalsHistone Deacetylase InhibitorHistone deacetylase inhibitionHuman Cell LineImidazoleInjection of therapeutic agentInstitutesMammalian CellMediatingMedicalMethodsMusN-terminalNeedlesNylonsOccupationsOne-Step dentin bonding systemPeptide Signal SequencesPeptidesPlasmid Cloning VectorPlasmidsPluripotent Stem CellsProteinsProtocols documentationPseudomonas aeruginosaPyrrolesRegenerative MedicineResearchRiskScienceSiteSourceStem cellsSurfaceSystemTestingTherapeuticType III Secretion System PathwayUnited States National Institutes of HealthUniversitiesViralViral VectorVirulentVirusVorinostatcancer initiationclinical applicationcytotoxicderepressioninduced pluripotent stem cellplasmid DNApromoterpublic health relevancesmall moleculetranscription factortumortumorigenesis
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Induced pluripotent stem cells (iPSCs) are the most expected cellular sources for regenerative medicine and hold tremendous therapeutic potential. Many groups have shown that adult fibroblasts and epithelial cells can be reprogrammed to a pluripotent, ESC-like state by viral or plasmid vector-mediated delivery of a small number of reprogramming factors. However, the use of viral vectors or plasmid DNA poses the danger of tumorigenesis through potential DNA integration. Therefore, it is necessary to develop new delivery methods for the transient expression of relevant reprogramming factors. Here, we propose to develop alternative methods for iPSC generation without using virus or plasmid DNA, thus making it safer for medical application. In the first aim, we will test whether we can generate iPSCs using bacteria-mediated protein injection. We will utilize a highly efficient protein delivery machinery, called type III secretion system (T3SS), encoded by a non-cytotoxic strain of Pseudomonas aeruginosa. In the second aim, we will test whether chemicals inducing site-specific HDAC inhibition can trigger transient expression of endogenous reprogramming factors and thus facilitate iPSC generation. Here we explore this possibility by utilizing a class of small molecules called Pyrrole imidazole polyamides (PIPs), which can bind to DNA in a sequence specific manner. Development of such safer iPSC induction methods will make the clinical application of iPSCs one step closer to reality. The University of Florida contributes substantially to the local and regional economy. In 2008, UF created 2,525 jobs and recent studies have shown that UF contributes nearly $6 billion annually to Florida's economy. The university employs about 34,000 people directly on its main campus and via UF organizations, such as the Institute of Food and Agricultural Sciences, is responsible for the creation of 74,894 jobs statewide. The current proposal will create 2 new jobs and retain 4 existing jobs.
PUBLIC HEALTH RELEVANCE: Induced pluripotent stem cells (iPSCs) are a highly anticipated cellular source for regenerative medicine and hold tremendous therapeutic potential. Presently, medical application of iPSCs is hampered by the danger of tumor formation. The current protocols utilizing viral or plasmid gene delivery methods, have a potential to damage the cellular genome permanently, and pose a risk for cancer initiation. Therefore, it is necessary to develop new delivery methods for the transient expression of appropriate reprogramming factors. Here we will attempt to overcome current limitations using (1) a highly efficient protein injection system and (2) chemicals to induce sequence specific gene reactivation. Development of such safer iPSC induction methods will make the clinical application of iPSCs one step closer to reality.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
iPSC Generation using Peptide Injection and Site-Selective HDAC Inhibition
-
批准号:7826066
-
项目类别:
-
资助金额:$50.0万
-
财政年份:2009
-
负责人:Takashi Hamazaki
-
依托单位:
海外基金